Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

A-3907 targets bile acid transport in the intestine and kidney for treating NASH, fibrosis

Dec. 2, 2020

New JAK inhibitors patented by Vimalan Biosciences

Dec. 2, 2020

Korea Research Institute of Bioscience and Biotechnology patents peptides for IBD

Dec. 2, 2020

Novel potent and selective thyroid hormone receptor beta agonists as therapeutic agents in NASH

Nov. 30, 2020

Merck initiates phase II study of MK-3655 in precirrhotic NASH

Nov. 27, 2020

Ionis licenses second NASH candidate to AstraZeneca

Nov. 27, 2020

Aclaris Therapeutics identifies new JAK inhibitors

Nov. 26, 2020

Topline phase IIa data on vibegron in IBS show primary endpoint not met

Nov. 25, 2020

shMKK4-224: an MKK4 inhibitor for liver regeneration

Nov. 25, 2020

Phase II data presented for saroglitazar in patients with PBC

Nov. 24, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.